Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.50 |
| ▸ | MGAM | O43451 | 8/20 | 0.50 |
| ▸ | SI | P14410 | 3/20 | 0.46 |
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LCT | P09848 | 1/20 | 0.46 |
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.46 |
| ▸ | UGCG | Q16739 | 3/20 | 0.46 |
| ▸ | AGL | P35573 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camiglibose SCHEMBL19510347 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL1201508 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL3952283 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL5186895 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL4604473 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL758524 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL5238483 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL614436 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL6794338 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL37446 | 0.99 | GAA (0.49) | GAAMGAMSIGBA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2506865-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES | Synergy Pharmaceuticals Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011069038-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES | SYNERGY PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| EP-1753766-A1 | TETRAAZABENZO(E)AZULENE DERIVATIVES AND ANALOGS THEREOF | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006033001-A1 | QUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005116034-A1 | TETRAAZABENZO[E]AZULENE DERIVATIVES AND ANALOGS THEREOF | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1372632-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002064130-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |